APUS.AMEXApimeds Pharmaceuticals Us, INC

8-K: Apimeds Merges with MindWave, Secures $100M PIPE

Sentiment:

Merger Announcement 2 December 2025 3:12 PM

📋All filings for Apimeds Pharmaceuticals Us, INC

Apimeds Pharmaceuticals US, Inc. merged with MindWave Innovations Inc, combining biotech and AI-driven digital asset treasury, supported by a concurrent PIPE of up to $100 million.

Delay expectedDelays beyond specified deadlines for the resale registration statement (45 days for filing, 75/120 days for effectiveness) will result in liquidated damages of 1% of the Redemption Value for each 30-day period.

Capital raiseA Private Investment in Public Equity (PIPE) offering of up to $100,000,000 is being consummated concurrently with the merger.A senior convertible note financing in an aggregate principal amount of up to $120,900,000 at an 8% original issue discount was entered into.$10,875,000 of the convertible notes principal amount was made available at closing.An additional $2,175,000 from the convertible notes will be funded upon the effectiveness of the resale registration statement.The investor has the right to purchase up to an aggregate of $13,075,000 of additional notes.The investor has the ability to purchase, subject to mutual consent, any amount remaining under the notes.If the PIPE is not consummated prior to or contemporaneously with the Closing, Bio Sub will deposit a $2,500,000 loan for TechyTrade's general operational purposes.

Better than expectedThe merger creates a diversified entity with potential for accelerated growth in both biotech and digital asset sectors.Significant capital is being raised through a PIPE of up to $100,000,000 and convertible notes of up to $120,900,000, providing substantial funding for future operations and clinical trials.The strategic integration of a "high-yield digital asset business with strong cash-flow potential" is expected to accelerate therapeutic programs.

Summary

Apimeds Pharmaceuticals US, Inc. (Acquiror) completed a merger with MindWave Innovations Inc (Company) on December 1, 2025, with MindWave surviving as a direct wholly-owned subsidiary of Acquiror.
The merger creates a dual-growth enterprise, integrating Apimeds' clinical-stage biopharmaceutical business focused on non-opioid pain management (Apitox) with MindWave's AI-driven Bitcoin treasury and digital asset yield generation platform.
MindWave's platform includes secure digital treasury wallets for corporations, AI-enhanced Bitcoin yield generation, and a validator-powered ecosystem supported by the $NILA token, positioning it as one of the first publicly traded, institutional-focused Digital Asset Treasury (DAT) models.
The transaction is supported by a concurrent Private Investment in Public Equity (PIPE) offering of up to $100,000,000.
A senior convertible note financing of up to $120,900,000 at an 8% original issue discount was also entered into, with $10,875,000 funded at closing and an additional $2,175,000 upon the effectiveness of the resale registration statement.
Existing MindWave stockholders collectively hold, on an as-converted and fully diluted basis, 90.9% of the equity capital of the Acquiror as of the Closing Date.
Apimeds will transfer its existing biopharmaceutical assets and liabilities to a wholly-owned subsidiary, Lokahi Therapeutics, Inc. (Bio Sub), to continue the Apimeds Business.
A reverse stock split of 1-for-10 for Acquiror Common Stock is planned, along with an amendment to the Acquiror's charter to change the par value from $0.01 to $0.001.
The Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan will be amended to increase the number of shares of Acquiror Common Stock issuable by 2,096,679, and a new 2025 Equity Incentive Plan will be adopted.

Sentiment

Score: 8

Explanation: The filing announces a strategic merger and significant capital raise, positioning the combined entity for diversified growth and accelerated development in two high-potential industries. The management comments are highly optimistic, and the financial backing is substantial, indicating a strong positive outlook for the company's future.

Positives

The merger creates a diversified organization combining high-growth biotechnology and institutional digital-asset financial technology, designed to drive long-term value and maximize stockholder returns.
Integration of a high-yield digital asset business with strong cash-flow potential is expected to accelerate Apimeds' therapeutic programs.
MindWave's platform is positioned at the forefront of institutional digital treasury management with its three-pronged strategic framework.
Significant capital infusion through a PIPE of up to $100,000,000 and convertible notes of up to $120,900,000 provides substantial funding for future operations and clinical trials.
MindWave's ownership of 1,000 Bitcoin, held in a segregated sub-wallet structure, is confirmed and free of encumbrances.

Risks

The businesses of Apimeds and MindWave may not be integrated successfully.
Synergies and growth from the transactions may not be fully realized or may take longer to realize than expected.
Potential adverse reactions or changes to business or employee relationships may result from the announcement or completion of the merger.
Failure to obtain or maintain required NYSE American listing approvals or satisfy continued listing standards.
Inability to consummate planned financings on acceptable terms or within expected timeframes.
Volatility in Bitcoin markets could impact collateral requirements.
Changes in Apimeds' capital structure and governance following the merger could have adverse effects on the market value of its securities.
The merger could distract management from ongoing business operations or cause substantial costs.
Apimeds may be unable to reduce expenses or access financing or liquidity.
Impact of any related economic downturn.
Risk of changes in governmental regulations or enforcement practices.

Future Outlook

The combined company is positioned to pursue diversified revenue streams and accelerate product development by integrating biopharmaceutical innovation with digital-asset financial technology. MindWave aims to be at the forefront of institutional digital treasury management. Apimeds plans to advance its clinical programs, particularly Apitox, towards Phase 3 trials. The company expects to realize synergies, manage debt levels, and integrate the two distinct business models.

Management Comments

Erik Emerson (CEO of Apimeds): "As Apimeds moves toward its Phase 3 clinical trial initiation, we continue to focus on financing and expansion. When I met the leadership team at MindWave and saw the strength and scalability of their business, it became clear this merger represented a unique opportunity. Biotech requires significant capital, and integrating a high-yield digital asset business with strong cash-flow potential will allow us to accelerate our therapeutic programs."
Dr. Vin Menon (Founder and CEO of MindWave): "The NYSE American listing, combined with our three-pronged approach to Bitcoin Treasury infrastructure, refined AI-supported yield capabilities, and a scalable multi-vertical ecosystem powered by the $NILA token, positions MindWave at the forefront of institutional digital treasury management. Joining forces with Apimeds creates a diversified organization designed to drive long-term value and maximize stockholder returns."

Industry Context

This merger represents a novel strategic move, combining the traditional, capital-intensive biopharmaceutical industry (focused on non-opioid pain management) with the rapidly evolving digital asset financial technology sector, particularly AI-driven Bitcoin treasury and yield generation. This diversification aims to leverage the potential cash flow and yield generation from digital assets to fund the development of biotech therapies, a unique approach in the public market landscape.

Comparison to Industry Standards

The filing describes MindWave as "one of the first companies to pursue a publicly traded, institutional-focused Digital Asset Treasury (DAT) model," suggesting a unique market position rather than direct comparison to existing industry benchmarks.
The company commits to maintaining directors and officers liability insurance on terms consistent with "market standards for companies of similar size and listing status," indicating adherence to general corporate governance benchmarks.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	Christopher Kim	NA	December 1, 2025	Resignation from Acquiror's board of directors.
Director	Hankil Yoon	NA	December 1, 2025	Resignation from Acquiror's board of directors.
Director	NA	Dr. Vin Menon	December 1, 2025	Appointed to Acquiror's board of directors as a Company Director Designee.
Director	NA	Amir Dossal	December 1, 2025	Appointed to Acquiror's board of directors as a Company Director Designee.
Chief Executive Officer	Erik Emerson	Dr. Vin Menon	December 1, 2025	Resignation as CEO of Acquiror; Dr. Menon designated by the Company.
President	NA	Erik Emerson	December 1, 2025	Appointed to serve as President of Acquiror.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Two directors (Christopher Kim and Hankil Yoon) resigned from the Acquiror Board. Two new directors (Dr. Vin Menon and Amir Dossal) were appointed, effective as of the Effective Time. The remaining five directors will continue to serve during the Interim Period. Following the Conversion Effective Time, the Company will have the right to designate individuals to replace these five Continuing Directors, ensuring compliance with NYSE American Governance Requirements.	December 1, 2025 (initial changes); Following Conversion Effective Time (subsequent changes)	Significantly shifts board control towards MindWave's designees post-merger, aligning governance with the new ownership structure and ensuring compliance with listing standards.
Certificate of Designation	A Certificate of Designation was filed for 7,263,865 shares of Series A Convertible Preferred Stock. These shares have no voting rights, are entitled to pro rata dividends/liquidation with common stock, have no redemption rights, and will automatically convert into 20 shares of Acquiror Common Stock per preferred share upon satisfaction of Required Approvals (stockholder and NYSE American listing approvals).	December 1, 2025	Establishes a significant class of equity that will convert into common stock, impacting future common stock dilution and shareholder rights, while initially limiting voting power.
Charter Amendment Proposal	Approval for an amendment to Acquiror's Amended and Restated Certificate of Incorporation to effectuate a 1-for-10 reverse stock split of Acquiror Common Stock and change the par value of capital stock from $0.01 to $0.001.	Following Action Effective Time	Aims to increase the per-share price of common stock, potentially to meet NYSE American listing requirements, and adjusts the nominal par value.
Equity Incentive Plan Amendment	Approval for an amendment to the Apimeds Pharmaceuticals US, Inc. 2024 Equity Incentive Plan to increase the number of shares of Acquiror Common Stock issuable under the plan by 2,096,679.	Following Action Effective Time	Increases the pool of shares available for employee and director incentives, which could lead to future dilution for existing shareholders.
New Equity Incentive Plan	Approval and adoption of the Apimeds Pharmaceuticals US, Inc. 2025 Equity Incentive Plan.	Following Action Effective Time	Establishes a new framework for future equity-based compensation, further enabling the company to attract and retain talent.
Indemnification and Insurance	Acquiror and the Surviving Corporation will indemnify and hold harmless current and former directors and officers for pre-Closing matters for a period of not less than six years and maintain directors and officers liability insurance on terms not less favorable than current coverage, subject to a premium cap.	December 1, 2025	Provides continuity of protection for management, which is crucial during a transition, and helps mitigate personal risk for directors and officers.

Related Party Transactions

Erik Emerson, former CEO of Apimeds and now President, is also the Bio Business Representative, with specific rights and monitoring responsibilities regarding the Bio Sub and its assets.
Dr. Vin Menon, the new CEO of Acquiror, is the founder and CEO of MindWave Innovations Inc, the acquired company. He also serves as CEO of AQUAE Impact and AQUAE Labs Pte Ltd, and Strategic Advisor of TechyTrade FZ-LLC (a wholly-owned subsidiary of MindWave).
Amir Dossal, a newly appointed director of Acquiror, is Chairman of AQUAE Impact, where Dr. Vin Menon also holds executive roles.
Certain stockholders of Acquiror (Majority Holders) entered into a Support Agreement to approve the merger-related proposals.
Voting Agreements were entered into with certain officers, directors, and stockholders to vote all shares of Acquiror Common Stock they hold in favor of the Note Conversion.

Stakeholder Impact

**Shareholders**: Potential for diversified growth and accelerated product development in both biotech and digital asset sectors. However, there is also risk related to integration challenges, market volatility (especially in Bitcoin), and potential dilution from new share issuances (preferred stock conversion, equity plans). Former MindWave stockholders gain significant control (90.9% equity).
**Employees**: Management changes include Erik Emerson becoming President and Dr. Vin Menon becoming CEO. The existing Apimeds Business will continue under the Bio Sub, preserving operations and potentially creating new opportunities within the combined entity.
**Customers**: Successful integration and accelerated product development could benefit future customers of Apimeds' therapies. MindWave's corporate customers using Digital Asset Treasury solutions would benefit from continued development and expanded infrastructure.
**Suppliers/Creditors**: The significant capital raise through PIPE and convertible notes could strengthen the company's financial position, potentially benefiting creditors and ensuring stability for suppliers.

Next Steps

Acquiror to prepare and file a written information statement (Schedule 14C) with the SEC concerning the Written Consent, Proposals, and Merger.
Disseminate the definitive Information Statement to Acquiror Stockholders.
Following the 20-calendar day waiting period after mailing the Definitive Information Statement, the approved Proposals (including Share Conversion, Note Conversion, Reverse Stock Split, 2024 Plan Share Increase, and 2025 Equity Incentive Plan adoption) will become effective.
As soon as reasonably practicable after the Action Effective Time, Acquiror to file Charter Amendment for Reverse Stock Split.
As soon as reasonably practicable after the Reverse Stock Split is effective, Acquiror to convert Acquiror Preferred Stock into Acquiror Common Stock.
Within five (5) Business Days following the Action Effective Time, Acquiror to file Form S-8 to register additional shares under the 2024 Plan.
Acquiror to file financial statements of the Company and pro forma financial information as an amendment to the 8-K no later than 71 calendar days after the required filing for this 8-K.
Acquiror to use its best efforts to consummate a private placement offering of up to $120,900,000.
Acquiror to obtain conditional approval of its listing application from NYSE American prior to the Conversion.
Company to deliver unaudited interim financial statements to Acquiror within 75 days after the Closing Date.
Bio Sub management to operate the Bio Business consistent with past practices during the Post-Closing Period (until $14.8M raised or 6 months post-closing).
Bio Sub not to incur Indebtedness exceeding $2,000,000 without CEO consent during the Post-Closing Period.
The Investor has the right to participate in up to 30% of any subsequent financing until the later of six months after the Commitment Period or the Notes maturity date.

Key Dates

Date	Description
March 3, 2025	Date since which Acquiror has filed or furnished all required registration statements, reports, schedules, forms, statements and other documents with the SEC.
March 31, 2025	Balance Sheet Date for the Company's audited financial statements.
November 29, 2025	Board of Directors of Apimeds Pharmaceuticals US, Inc. adopted resolutions for the creation of Series A Convertible Preferred Stock.
December 1, 2025	Closing Date of the Merger Agreement, execution of the Merger Agreement, Acquiror Support Agreement, Securities Purchase Agreement, E.F. Hutton Warrant, and Certificate of Designation. Effective Time of the Merger. Erik Emerson resigned as Chief Executive Officer of Acquiror, and Dr. Vin Menon was appointed as the new Chief Executive Officer of Acquiror. Erik Emerson was appointed to serve as President of Acquiror.
Within 2 Business Days of Closing	Bio Sub shall deposit $2,500,000 from its available cash into an account designated by the Company for general operational purposes of TechyTrade, if the Private Placement Offering has not been consummated.
Within 5 Business Days following the Closing	Acquiror shall cause the assets and liabilities of Acquiror existing immediately prior to the Closing to be transferred to Bio Sub.
Within 45 days of closing	Acquiror is required to file a resale registration statement on Form S-1 for the Notes.
Within 75 days (or 120 days in the event of a full SEC review) of closing	The resale registration statement for the Notes is required to be declared effective.
Within 75 days after the Closing Date	The Company is to deliver unaudited interim financial statements prepared in accordance with GAAP and Regulation S-X to Acquiror.
As promptly as reasonably practicable after the Closing Date	Acquiror will prepare and file a written information statement (Schedule 14C) with the SEC concerning the Written Consent, Proposals, and Merger.
Following the expiration of the 20-calendar day waiting period after mailing the Definitive Information Statement	The Proposals approved by the Written Consent, including the Share Conversion, Note Conversion, Reverse Stock Split, 2024 Plan Share Increase, and 2025 Equity Incentive Plan adoption, shall become the approved and binding corporate actions of the Acquiror (Action Effective Time).
As soon as reasonably practicable after the Action Effective Time	Acquiror shall cause the Charter Amendment to be filed with the DE SOS to implement the Reverse Stock Split.
Within five (5) Business Days following the Action Effective Time	Acquiror shall file, or cause to be filed, with the SEC a registration statement on Form S-8 to register the additional shares of Acquiror Common Stock reserved for issuance under the 2024 Plan.
As soon as reasonably practicable after the Reverse Stock Split is effective	Acquiror shall cause the Acquiror Preferred Stock to be converted into the applicable number of shares of Acquiror Common Stock.
Until the earlier of Acquiror raising $14,800,000 for Bio Sub or six months following the Closing	The Bio Business shall be preserved and operated in a manner consistent in all material respects with the past practices of the Acquiror prior to the Closing (Post-Closing Period).
12 month anniversary of their issuance	Maturity date for the senior convertible notes.
Until the later of six months after the Commitment Period or the Notes maturity date	The Investor has the right to participate in up to 30% of any subsequent financing.
December 1, 2030	Termination Date for the E.F. Hutton Warrant.

Recommendation

hold

The merger presents a compelling strategic diversification into high-growth sectors (biotech and digital assets) with substantial capital infusion. However, the significant change in control, the complexity of integrating two disparate businesses, and the inherent volatility of the digital asset market introduce considerable execution risk. While the long-term potential is attractive, a 'Hold' recommendation is prudent until there is clearer evidence of successful integration, realization of stated synergies, and stable performance of the combined entity, particularly given the substantial equity shift to MindWave's former shareholders. The PIPE and convertible notes provide necessary capital, but the dilutive effects and the operational challenges of managing two distinct business models warrant a cautious stance for now.

Keywords

Biotechnology, Digital Assets, Bitcoin, AI, Treasury Management, Merger, Pharmaceuticals, NYSE American, Apitox, Pain Management, $NILA Token, PIPE, Convertible Notes, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.